ZYDUSLIFE Zydus Lifesciences Ltd Dividend Policy Changes Announcement 2023 - Increase in Dividend Rate Zydus Lifesciences has received final approval from the USFDA for its Indomethacin suppositories with a Competitive Generic Therapy (CGT) designation, granting 180-day CGT exclusivity to market the product..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd